VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. The company is headquartered in Basel, Basel-Stadt and currently employs 42 full-time employees. The company went IPO on 2021-04-09. The firm trough it's subsidiaries operates as a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe rare conditions for which there is a significant unmet medical need.

Industry: Biological Products, (No Diagnostic Substances) Peers: AC Immune SA ADC Therapeutics SA CRISPR Therapeutics AG